Truist lowered the firm’s price target on Fresenius Medical to $22 from $24 and keeps a Hold rating on the shares. The firm cites the company’s mixed Q2 results featuring AOI strength driven by better margins, continued strong cost controls, and sluggish volume trends tied to a drag from excess mortality, the analyst tells investors in a research note. Fresenius cash flow remains solid although the quarter saw some timing impacts, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care AG Outlines Corporate Objectives
- Fresenius Medical still sees FY24 revenue growth in low- to mid-single digits
- Fresenius Medical reports Q2 EPS EUR0.64 vs. EUR0.48 last year
- Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024
- Fresenius Medical Care Sees Strong Q2 Progress